ANNUAL REPORT FY2024 13 Directors’ Report The Directors present their report, together with the financial statements, on the Consolidated Entity (referred to hereafter as the 'Consolidated Entity') consisting of Nyrada Inc. (referred to hereafter as the 'Company' or 'Parent entity') and the entities it controlled at the end of, or during, the year ended 30 June 2024. Directors The following persons were directors of Nyrada Inc. during the whole of the financial year and up to the date of this report, unless otherwise stated: John Moore Non-Executive Chair Rüdiger Weseloh Non-Executive Director Marcus Frampton Non-Executive Director Christopher Cox Non-Executive Director Ian Dixon Non-Executive Director Gisela Mautner Non-Executive Director John Moore Non-Executive Chair, joined the Board in June 2019 John Moore is an experienced executive with a diverse background in leadership roles across various industries. He currently serves on the boards of two private companies and three public companies. Recently, John became a Director of Phase Holographic, a company specializing in live cell imaging systems for life science researchers. Phase Holographic's stock is traded on the Swedish Spotlight market and will soon be listed on the OTCQB market in the USA. John will transition from his role as Chairman of Cormetech to being a shareholder and Director. He remains the Chairman of Scientific Industries (SCNDOTCQB), a producer of laboratory instruments for the life sciences industry, and Trialogics, a clinical trial informatics business. John's prior experience includes serving as CEO of Acorn Energy from 2006 to 2015. During his tenure, the CoaLogix business was acquired for US$11 million and later sold for US$101 million. Additionally, the Comverge business was listed in the US before being sold to Constellation Energy. In 2002, John was a Partner and CEO of Edson Moore Healthcare Ventures, where he oversaw the acquisition of a portfolio of sixteen drug delivery investments from Elan Pharmaceuticals for US$148 million. John is a graduate of Rutgers University, US, and brings a wealth of experience and strategic insight to his current roles. Interest in shares and options 1,691,756 shares 2,400,000 unlisted options Special responsibilities Chair of the Board. Member of Audit & Risk Committee Member of Remuneration & Nomination Committee Directorship held in other listed entities (last 3 years) N/A Qualifications John graduated from Rutgers University with a Bachelor of Arts degree in History.
RkJQdWJsaXNoZXIy MjE2NDg3